Achievement and innovation are both realized! Columbotai Biotech (06990)'s Path to Advanced Biopharma
The Zhitong Finance App learned that on August 17, Colunbotai Biotech (06990) released its 2026 interim results and used two landmark developments to answer questions about the leap from R&D Biotech to full-industry chain Biopharma.
First, poor commercialization expectations have been fully repaired. In the first half of 2026, Kolumbotai's commercial revenue surpassed the full year of 2025, and the growth momentum was rapid. This is due to rapid dosage and clear and efficient commercialization strategies for products such as lucansatuzumab (Sac-TMT, Cathailai®) after being covered by medical insurance. As a result, the company's independent commercial chassis has been completely consolidated, and a closed loop of value has been achieved in the entire industry chain from product R&D and production to commercialization.
Second, the global clinical research card won. A number of registered studies of sAC-TMT reached the main goal and obtained double positive results in the first global phase III study, forming a strategic map for expansion from single drug to syndication, from backline to front, from China to the world, and multiple indications. Against the backdrop of increased competition on ADC single drugs/combined tracks and extremely rare benefits for both PFS and OS, this TROP2 ADC has steadily entered the world's first tier, and is expected to reshape the global tumor treatment pattern.
Currently, the narrative logic of China's innovative drugs has long been iterated: the market is no longer agitated by a single licensing announcement, but is shifting to a hierarchical assessment of independent commercialization success, clinical promotion efficiency, and global capabilities. Only continuous performance implementation and R&D breakthroughs can support the long-term value of the enterprise. With its efficient R&D capabilities and operational resilience throughout the entire industry chain, Collumbotai has become a representative sample for innovative domestic pharmaceutical companies to advance to BioPharma and even global MNC.
01 A key leap forward in commercialization: endogenous hematopoietic closed-loop molding
In 2026 H1, the first batch of commercial product matrices of Colunbotai achieved large-scale deployment, driving continuous improvement in operating cash flow — the company's total revenue was 978 million yuan, of which commercial revenue was 657 million yuan, a key leap forward in endogenous hematopoiesis.
Commercialization capabilities never come out of thin air. Collumbotai adopted a “win before listing” style of play — forming a core team and refining the promotion strategy before the first NDA was approved. This pre-layout successfully connected the commercialization of various products, including the world's “potentially best-in-class” TROP2 ADC SaC-TMT, the world's first PD-L1 tagolimab (Cotailai®) to treat 1L NPC, EGFR monoclonal cetuximab (Dattailai®), which is clinically equivalent to the original drug, and the first domestically produced HER2 ADC bodutrastuzumab (Shutelai®) to treat 2L+ HER2 BC, and promoted the inclusion of three products with five indications under medical insurance.
With the opening of the medical insurance window in 2026, the product has entered a complete release cycle. Combined with expert recognition of high-quality clinical data of the product and changes in treatment concepts, and the company's all-round efforts in product accessibility, driving strong commercial revenue growth, the R&D results accumulated in the early stages are being transformed into operating results at an accelerated pace.
More importantly, this growth momentum is far from being unleashed. Currently, a total of 3 indications, sAC-TMT and bordotrazumab, have been reviewed in the 2026 medical insurance catalogue, and the growth potential will be further strengthened; in addition, the NDA for the RET inhibitor lenboltinib fumarate (Nintailai®) has been accepted. This small-molecule targeted drug is ready to go, further strengthening the first batch of commercial product matrices and continuing to increase cash flow reserves.
Behind a series of developments, it represents the formal formation of a systematic and replicable innovation industry chain. The deeper signal is that Colombotech already has integrated drug development capabilities from R&D and production to commercialization. This is the core and hardest competitiveness to replicate in Biotech's advancement to Biopharma.
02 Leading the world in single products, the platform drives long-term innovation
If commercialization has verified the company's current hematopoietic capacity, the depth and breadth of the pipeline determines its long-term growth.
The core anchor point, SAC-TMT, is becoming the leading single product of China's innovative drugs going global.
Domestically, 4 single-drug back-line indications of SAC-TMT have been approved for marketing, and 5 phase III first-line single drugs/combination studies are progressing in an orderly manner, and the clinical and commercial value is highly deterministic. Overseas, SAC-TMT has moved from early approval to the implementation period. In 17 global phase III clinical trials led by partner MSD, the Trofuse-005 study on endometrial cancer has taken the lead in obtaining positive results for both PFS and OS, making it a benchmark case for domestic authorized single products to pass international clinical tests.
However, the success of SAC-TMT is inseparable from a clear and systematic development strategy, and the four main lines are being promoted at various levels:
1. From single drugs to combinations, build a rich level of “ADC+”, and use mechanism collaboration as the underlying logic to carry out combination with drugs with different mechanisms such as PD- (L) 1, PD-1/VEGF double antibodies, and small molecule TKI;
2. Extend from the back line to the front line, and proactively arrange assistants/new aids to maintain treatment scenarios throughout the entire course of the tumor;
3. Comprehensive coverage of high-incidence solid tumors, extending from LC/BC to gynecologic tumors/GI/GU, and continuously broadening the applicable population and market ceiling;
4. Domestic and global collaborative promotion, relying on dual clinical systems at home and abroad to maximize the commercial value of products.
This hierarchical R&D route has been proven by hard core progress that has been implemented one after another. In the future, as more Phase III data is read out, and the “ADC+” first-mover advantage is superimposed, the medium- to long-term value flexibility of SAC-TMT is fully flexible. At the same time, global research data also complements and verifies each other in both directions with local clinical data, forming a virtuous cycle of collaborative empowerment at home and abroad — this is also the key that distinguishes SAC-TMT from ordinary “authorized overseas” single products.
If you want to grow into a first-class biopharma, you can't just rely on single products to support it. Based on the OptiDC™ integrated ADC development platform, Colombotech has established a three-tier ADC and new DC therapy tier, forming a sustainable innovation pattern of “short-term implementation, mid-term commitment, and long-term breakthrough”, nurturing a wider space for growth:
In the short term, sAC-TMT and bodutrastuzumab were commercialized based on unique molecular designs to quickly build a basic market;
In the medium term, innovative assets such as SKB315 (CLDN18.2 ADC), SKB410 (Nectin-4 ADC), SKB571 (novel dual-antibody ADC), SKB500 (B7-H3 ADC), and SKB105 (ITGB6 ADC) form differentiated reinforcements, which not only complement existing products in indications, but are also expected to further improve efficacy and safety;
In the long term, Columbotai will freely combine the three core components of payload, connector, and target, lay out the next generation of novel DC therapies, and incubate a new generation of molecules with global competitiveness from a forward-looking perspective.
Furthermore, in the field of ADC+IO, which will determine the future pattern of the industry, Columbotai is building intergenerational barriers through a two-pronged approach of collaborative therapy and integrated development.
On the one hand, a matrix of integrated cooperative therapy was built - based on PD-L (1) immunotherapy, combined trials with ADC were carried out. Among them, the gold combination of the SAC-TMT+k drug progressed the fastest. Two first-line phase III studies of first-line lung cancer have reached the main goal, making it the world's first ADC+IO therapy proven in the field of first-line lung cancer; 9 other global phase III studies are progressing simultaneously. At the same time, we are actively exploring the potential of combined use of novel immunotherapies such as PD-1/VEGF dual antibodies with multiple ADC assets to further expand treatment benefits. Among them, SKB118 (PD-1/VEGF double antibody) +sAC-TMT has been approved for clinical trials.
On the other hand, the layout of “integrated development” ADC products with a synergetic mechanism, such as SKB103 (TAA-IO dual-antibody ADC) and SKB565 (novel dual-load ADC), seize the opportunity for technological iteration.
This full-dimensional layout, from joint drug use to source innovation, allows Colunbott not only to lead the clinical application of “ADC+IO”, but also to lead the “2.0" era of integrated ADCs and stand at the head of the development trend of integrated ADCs.
Overall, from leading the world in major core products, to the orderly iteration of multi-level pipelines, to forward-looking cards for next-generation treatments, Colombotech has formed an innovative supply system with clear hierarchies and clear intergenerational divisions, building a strong technical momentum for long-term global competition.
03 Global Upgrading: Triple Capability Transition to World-Class Biopharma
From “leading China” to “global upgrading”, Collumbotai is implementing a “three-step” strategy — first building a local industrial chain system, then accumulating global experience and brand reputation through international cooperation, and finally achieving a strategic transformation from “borrowing a ship to go overseas” to “going overseas independently”.
In the domestic market, Colunbotai has fully completed the “R&D - clinical - production - commercialization” link: the R&D side has platform innovation capabilities, the clinical side has efficient transformation and promotion efficiency, the production side has independent ADC production capacity in parallel with CMO, and the commercial side has achieved endogenous hematopoiesis through self-built professional teams.
With a comprehensive operating system, its globalization progress will follow the trend:
Start by “borrowing a ship to go overseas”, rely on top MNC's global clinical resources and commercialization network to rapidly advance global multi-center clinical trials of core products, achieve milestone benefits, and accumulate global project experience and complete preliminary reserves; then advance to “shipbuilding and going overseas”, explore diversified overseas routes on the basis of mature overseas cooperation, gradually carry out international multi-center registration clinical research and establish a commercialization system to achieve independent overseas travel in the true sense of the word.
This process has also simultaneously driven the company's all-round upgrading in terms of performance, business, and strategy.
In terms of performance, commercial products continued to be released, and endogenous cash flow was abundant, providing stable financial support for global R&D investment, and reliance on financing and BD benefits;
In terms of business, the clinical value of SAC-TMT continues to rise, the platform pipeline hierarchy and ADC joint layout continue smoothly, and the product's hard power is sufficient to support global market competition;
Strategically, the domestic industry continues to release value in a closed loop, and the overseas layout is being implemented step by step. Both sides reinforce each other, and jointly push Colunbotte to leap from a local innovative pharmaceutical company to a global Biopharma.
Along the way, Relying on the two-way support of the value and global layout of the entire industry chain, and through the triple transformation of performance, business, and strategy, Columbotai has verified its core qualifications to grow into a global Biopharma, and has also provided a mature model that can be replicated and learned from for the advancement of the globalization of Chinese innovative pharmaceutical companies.